Absolute Climate and Northern Trust Collaborate to Offer Independent Certification and Lifecycle Management for Digital Carbon Credits

Autonomix Medical's technology and findings from its first-in-human proof-of-concept study will be featured in a podium presentation at the 2025 CIRSE Annual Congress. The presentation will focus on pain mitigation in pancreatic adenocarcinoma through transvascular radiofrequency ablation. The event highlights the company's progress in advancing precision nerve-targeted treatments.

Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company specializing in precision nerve-targeted treatments, has announced that its technology and findings from the first phase of its first-in-human proof-of-concept (PoC) clinical trial will be featured in a podium presentation at the 2025 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress. The event, scheduled to take place from September 13 to 17, 2025, in Barcelona, Spain, will highlight the company's advancements in the treatment of pancreatic cancer.

The presentation, titled "Pain mitigation in pancreatic adenocarcinoma: an analysis of neurolysis via transvascular radiofrequency (RF) ablation," will be delivered by Marco Bedoya, the company's Vice President of Research and Development. It will be part of SPHAIRE, CIRSE's interactive area dedicated to exploring the potential of artificial intelligence (AI) in interventional radiology (IR). The session, titled "AI in IR: Machine Learning, SOP and Collaborative Development," will be held on Monday, September 15, from 4:15 PM to 5:15 PM CEST.

The presentation will focus on the use of AI to enhance decision-making in IR, develop predictive models, improve image quality, support navigation, and reduce radiation doses. Specifically, Autonomix's technology aims to address the debilitating pain associated with pancreatic adenocarcinoma, a condition that currently lacks a reliable solution. The company's first-in-class platform system technology includes a catheter-based microchip sensing array capable of detecting and differentiating neural signals with greater sensitivity than existing technologies.

The 40th CIRSE Annual Congress, with the theme "Pioneering Progress," is a must-attend event for healthcare professionals providing minimally invasive image-guided treatments. The congress offers a wide range of hands-on training sessions, allowing delegates to learn from experienced professionals and advance their technical skills.

For more information about the CIRSE Annual Congress, please visit the event website [here](https://www.cirse2025.com).

References:
https://finviz.com/news/161154/autonomix-medical-inc-announces-abstract-accepted-for-podium-presentation-at-the-2025-cirse-annual-congress
https://www.nasdaq.com/press-release/autonomix-medical-inc-announces-abstract-accepted-podium-presentation-2025-cirse
https://www.stocktitan.net/news/AMIX/autonomix-medical-inc-announces-abstract-accepted-for-podium-41s9snjx36nb.html